Garcia JM, Marugan RB, Garcia GM, Lindeman MLM, Abete JF, Terron SDC. TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine. World J Gastroenterol 2003; 9(6): 1261-1264 [PMID: 12800236 DOI: 10.3748/wjg.v9.i6.1261]
Corresponding Author of This Article
Dr. Rafael Barcena Marugan, Department of Gastroenterology, Hospital Ramony Cajal, Ctra. Colmenar, Km 9.1, 28034 Madrid, Spain. rbarcena.hrc@salud.madrid.org
Article-Type of This Article
Viral Hepatitis
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jun 15, 2003; 9(6): 1261-1264 Published online Jun 15, 2003. doi: 10.3748/wjg.v9.i6.1261
TT virus infection in patients with chronic hepatitis B and response of TTV to lamivudine
Javier Moreno Garcia, Rafael Barcena Marugan, Gloria Moraleda Garcia, M Luisa Mateos Lindeman, Jesus Fortun Abete, Santos del Campo Terron
Javier Moreno Garcia, Rafael Barcena Marugan, Gloria Moraleda Garcia, Santos del Campo Terron, Department of Gastroenterology, Hospital Ramony Cajal, Madrid, Spain
M Luisa Mateos Lindeman, Department of Microbiology, Hospital Ramony Cajal, Madrid, Spain
Jesus Fortun Abete, Department of Infectious Diseases, Hospital Ramony Cajal, Madrid, Spain
Author contributions: All authors contributed equally to the work.
Supported by Fundacion Manchega de Investigaciony Docencia en Gastroenterologia
Correspondence to: Dr. Rafael Barcena Marugan, Department of Gastroenterology, Hospital Ramony Cajal, Ctra. Colmenar, Km 9.1, 28034 Madrid, Spain. rbarcena.hrc@salud.madrid.org
Telephone: +34-91-3368093 Fax: +34-91-7291456
Received: February 25, 2003 Revised: March 4, 2003 Accepted: March 16, 2003 Published online: June 15, 2003
Abstract
AIM: To investigate the responses of TT virus (TTV) and hepatitis B virus (HBV) to a long-term lamivudine therapy.
METHODS: Sixteen patients infected with both TTV and HBV were treated with lamivudine 100 mg daily for 30 mo. Blood samples were drawn at the beginning of the therapy and subsequently at month 3, 6, 9, 12 and 30. Serum TTV was quantified by real time PCR and serum HBV was detected by hybridization assay and nested polymerase chain reaction.
RESULTS: TTV infection was detected in 100% of HBV-infected patients. Loss of serum TTV DNA after one year of treatment occurred in 1/16 (6%) patients. At the end of therapy, TTV DNA was positive in 94% of them. The decline of HBV viremia was evident at 3 mo after therapy and the response rate was 31%, 44%, 63%, 50% and 50% at month 3, 6, 9, 12 and 30, respectively.
CONCLUSION: TTV replication is not sensitive to lamivudine and is highly prevalent in HBV-infected patients.
